The FDA approved the first time in 30 years the indication of antitumor Nexavar for treating liver cancer. Also, the drug received approval from European authorities. The FDA approval was based on positive results achieved in international phase III study, placebo-SHARP (Sofafenib HCC Assessment Randomized Protocol, “Protocol assessment randomized to sorafenib in HCC”) which demonstrated [...]